Namas Rajaie, Rubin Bernard, Adwar Wamidh, Meysami Alireza
Department of Internal Medicine, Division of Rheumatology, Henry Ford Hospital, Wayne State University, Detroit, MI 48202, USA ; Department of Internal Medicine, Division of Rheumatology, University of Michigan, 1150 W. Medical Center Drive, SPC 5680, Ann Arbor, MI 48109, USA.
Department of Internal Medicine, Division of Rheumatology, Henry Ford Hospital, Wayne State University, Detroit, MI 48202, USA.
Case Rep Rheumatol. 2014;2014:516362. doi: 10.1155/2014/516362. Epub 2014 Nov 27.
Case. We report a rare case of hydralazine-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. A 75-year-old African American woman with history of high blood pressure on hydralazine for 3 years presented with acute onset of shortness of breath and hemoptysis. Lab workup revealed a severe normocytic anemia and a serum creatinine of 5.09 mg/dL (baseline 0.9). Bronchoscopy demonstrated active pulmonary hemorrhage. A urine sample revealed red cell casts and a renal biopsy demonstrated pauci-immune, focally necrotizing glomerulonephritis with small crescents consistent with possible anti-neutrophil cytoplasmic antibody-positive renal vasculitis. Serologies showed high-titer MPO-ANCA and high-titer anti-histone antibodies. She was treated with intravenous steroids and subsequently with immunosuppression after cessation of hydralazine. The patient was subsequently discharged from hospital after a rapid clinical improvement. Conclusion. Hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis is a rare adverse effect and can present as a severe vasculitic syndrome with multiple organ involvement. Features of this association include the presence of high titer of anti-myeloperoxidase anti-neutrophil cytoplasmic antibody with multiantigenicity, positive anti-histone antibodies, and the lack of immunoglobulin and complement deposition. Prompt cessation of hydralazine may be sufficient to reverse disease activity but immunosuppression may be needed.
病例。我们报告一例罕见的肼屈嗪诱导的抗中性粒细胞胞浆抗体相关性血管炎。一名75岁的非裔美国女性,有高血压病史,服用肼屈嗪3年,出现急性呼吸困难和咯血。实验室检查显示严重正细胞性贫血,血清肌酐为5.09mg/dL(基线值为0.9)。支气管镜检查显示有活动性肺出血。尿液样本显示有红细胞管型,肾活检显示寡免疫性、局灶性坏死性肾小球肾炎伴小新月体,符合可能的抗中性粒细胞胞浆抗体阳性肾血管炎。血清学检查显示高滴度的髓过氧化物酶抗中性粒细胞胞浆抗体和高滴度的抗组蛋白抗体。她接受了静脉注射类固醇治疗,停用肼屈嗪后随后接受了免疫抑制治疗。患者在临床迅速改善后随后出院。结论。肼屈嗪诱导的抗中性粒细胞胞浆抗体阳性肾血管炎是一种罕见的不良反应,可表现为累及多个器官的严重血管炎综合征。这种关联的特征包括存在高滴度的抗髓过氧化物酶抗中性粒细胞胞浆抗体且具有多抗原性、抗组蛋白抗体阳性以及缺乏免疫球蛋白和补体沉积。迅速停用肼屈嗪可能足以逆转疾病活动,但可能需要免疫抑制治疗。